| | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
FDA pumps brakes on Sanofi's $3.7B multiple sclerosis bet, imposing partial hold over liver injuries Teladoc's Jason Gorevic bullish on long-term growth amid turbulent market, growing telehealth competition FDA recommends Pfizer, Moderna update their COVID boosters to target omicron subvariants Intuitive, Siemens score FDA nod to add 3D imaging to robotic lung biopsies Hit with 'current market realities,' Heron axes more than a 3rd of 300-person workforce Fierce Next Gen: As gene therapies proliferate, pharma and payers look to avoid 'cost shocks' HHS buys up 105M Pfizer COVID-19 vaccine doses for fall campaign amid money crunch Hyperfine CEO steps down after one year Fierce Next Gen: Eikon drops hints at early pipeline, plans for $660M-plus reservoir Banner Health teams with Hue Health, Flume Health for new direct primary care plan WindTree has the clinical results it wants—but is missing the bull market Novartis brings radiotherapy production back online, touts expansion plans Philips taps Biodesix’s blood tests for lung cancer screening system Featured Story | By Nick Paul Taylor The $3.7 billion centerpiece of Paul Hudson’s R&D strategy for Sanofi has hit a setback. Seeing cases of drug-induced liver injury, the FDA has slapped a partial clinical hold on phase 3 trials of the candidate, raising still more doubts about the merits of Sanofi’s Principia Biopharma takeover. read more |
| |
|---|
|
Top Stories By Heather Landi Teladoc CEO Jason Gorevic is bullish that Teladoc can win in the market in the long run despite current market volatility and growing competition from well-funded startups. As virtual care evolves and becomes more integrated into healthcare, Teladoc has the scale, capabilities and depth of expertise to lead the sector, he told Fierce Healthcare in a recent interview. read more By Zoey Becker After the FDA's independent vaccine committee voted to update COVID-19 shots, the agency recommends that manufactures update their vaccines to target omicron subvariants BA.4 and BA.5. read more By Andrea Park Too many cooks in the kitchen may spoil the broth, but medtech developers are betting that adding increasingly more tech tools to the operating room will only improve procedure success rates. read more By Gabrielle Masson Heron Therapeutics has joined the gaggle of biotechs laying off staff, cutting a third of its workforce as part of restructuring efforts that could bring an annual $43 million in savings. read more By Eric Sagonowsky Increasingly, cell and gene therapies are changing the treatment landscape for cancers and rare diseases. But how will the system pay for them? read more By Robert King HHS reached a $3.2 billion deal with Pfizer to purchase 105 million doses of the drug manufacturer's COVID-19 vaccine in anticipation of a fall campaign. read more By Andrea Park “I am disappointed to have to step back from my role as president and CEO of Hyperfine. It has been an honor to lead the company through our first full year of commercialization and our transition to becoming a publicly listed company,” said Dave Scott, citing personal reasons. read more By Max Bayer After raising more than $660 million in less than a year, Eikon Therapeutics' future plans are coming into clearer view, with an oncology pipeline underway as the star-studded biotech looks to capitalize on—and expand—Nobel Prize-winning tech. read more By Paige Minemyer Banner Health has signed on with Hue Health and Flume Health to launch a new health plan built around direct primary care. read more By Gabrielle Masson WindTree Therapeutics has the clinical results it wants—but is missing the bull market, meaning the biotech is exploring strategic options amid the market downturn. read more By Angus Liu Novartis has put an end to a radiotherapy production hiccup, and expansions are already underway. The Swiss pharma is investing to expand the very two manufacturing facilities that caused the latest supply freeze for the U.S. read more By Conor Hale To gain a clearer picture when screening people for the early signs of lung cancer, Philips is looking to bolster its CT scanning approach with blood-based tests developed by Biodesix. read more |
